95 related articles for article (PubMed ID: 11779404)
1. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma.
Metharom P; Ellem KA; Schmidt C; Wei MQ
Hum Gene Ther; 2001 Dec; 12(18):2203-13. PubMed ID: 11779404
[TBL] [Abstract][Full Text] [Related]
2. Gene transfer to dendritic cells induced a protective immunity against melanoma.
Metharom P; Ellem KA; Wei MQ
Cell Mol Immunol; 2005 Aug; 2(4):281-8. PubMed ID: 16274626
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
4. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz J; Brück J; Lenz J; Knop J; Tüting T
Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of dendritic cells loaded with a fusion mRNA encoding tyrosinase-related protein 2 and enhanced green fluorescence protein on B16 melanoma.
Fukui M; Nakano-Hashimoto T; Okano K; Maruta Y; Suehiro Y; Hamanaka Y; Yamashita H; Imai K; Kawano MM; Hinoda Y
Tumour Biol; 2004; 25(5-6):252-7. PubMed ID: 15627888
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
9. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.
Shibagaki N; Udey MC
Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050
[TBL] [Abstract][Full Text] [Related]
11. Murine tyrosinase expressed by a T7 vector in bone marrow-derived dendritic progenitors effectively prevents and eradicates melanoma tumors in mice.
Li J; Holmes LM; Franek KJ; Wagner TE; Wei Y
Cancer Gene Ther; 2000 Nov; 7(11):1448-55. PubMed ID: 11129287
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.
Lizée G; Gonzales MI; Topalian SL
Hum Gene Ther; 2004 Apr; 15(4):393-404. PubMed ID: 15053864
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
[TBL] [Abstract][Full Text] [Related]
15. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
16. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.
Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J
Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
18. Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector.
Strobel I; Krumbholz M; Menke A; Hoffmann E; Dunbar PR; Bender A; Hobom G; Steinkasserer A; Schuler G; Grassmann R
Hum Gene Ther; 2000 Nov; 11(16):2207-18. PubMed ID: 11084678
[TBL] [Abstract][Full Text] [Related]
19. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
20. CD4 T cell-mediated masking effects of the immunogenicity of tumor-associated antigens are qualitatively and quantitatively different depending on the individual antigens.
Okano S; Matsumoto Y; Yoshiya S; Yamashita Y; Harimoto N; Ikegami T; Shirabe K; Harada M; Yoshikai Y; Maehara Y
Fukuoka Igaku Zasshi; 2013 Jan; 104(1):1-14. PubMed ID: 23600320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
